Background: Multiple sclerosis (MS) carries high morbidity and shortens life span. While there is recent recognition of other US minority populations such as blacks and Hispanics being affected with MS, examination of MS-specific mortality trends by race/ethnicity has been lacking. Objective: To investigate MS mortality rates and trends in the United States by sex, age, and race/ethnicity. Methods: We used the Compressed Mortality data file for 1999–2015 in the Wide-ranging online Data for Epidemiological Research system developed by the Center for Disease Control and Prevention to calculate the age-adjusted (US 2000 standard population) and age-specific MS mortality rate (per 100,000) by race/ethnicity and sex over time. Five mutually exclusive racial/ethnic groups were included in the analysis: non-Hispanic (NH) white, NH black, NH Asian or Pacific Islander (API), NH American Indian or Alaska Native, and Hispanic. Results: The average annual age-adjusted MS mortality rate was highest among NH whites (0.90 for males and 1.50 for females) immediately followed by NH blacks (0.75 for males and 1.42 for females), and lowest among APIs (0.05 for males and 0.12 for females). Statistically significant, increasing trend in age-adjusted MS mortality was observed during 1999–2015 among NH whites and NH blacks regardless of sex, more substantially in the latter. Age-specific MS mortality patterns showed NH blacks had the highest rate under age 55 and NH whites had the highest rate after that age point. For these 2 groups, MS mortality increased with age in both sexes and peaked at ages 55–64 for NH blacks and 65–74 for NH whites before declining substantially, while for Hispanic and API groups the risk plateaued after age 55. Conclusion: MS-specific mortality trends demonstrate distinctive differences by race/ethnicity and age. The observations that whites and females are more likely to die from MS is in line with the overall understanding that these groups are affected more by MS. However, the findings of blacks dying at an earlier age and having more substantially increasing mortality trends than whites suggest that MS burden weighs unequally by race. Further investigation into these trends may provide additional evidence into risk or protective factors within each group.

1.
Noonan CW, Kathman SJ, White MC: Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology 2002; 58: 136–138.
2.
Jacobson DL, Gange SJ, Rose NR, Graham NM: Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 1997; 84: 223–243.
3.
Manouchehrinia A, Tanasescu R, Tench CR, Constantinescu CS: Mortality in multiple sclerosis: meta-analysis of standardised mortality ratios. J Neurol Neurosurg Psychiatry 2016; 87: 324–331.
4.
Chruzander C, Johansson S, Gottberg K, et al: A 10-year follow-up of a population-based study of people with multiple sclerosis in Stockholm, Sweden: changes in disability and the value of different factors in predicting disability and mortality. J Neurol Sci 2013; 332: 121–127.
5.
Llorca J, Guerrero-Alonso P, Prieto-Salceda D: Mortality trends of multiple sclerosis in Spain, 1951–1997: an age-period-cohort analysis. Neuroepidemiology 2005; 24: 129–134.
6.
Langer-Gould A, Brara SM, Beaber BE, Zhang JL: Incidence of multiple sclerosis in multiple racial and ethnic groups. Neurology 2013; 80: 1734–1739.
7.
Wallin MT, Kurtzke JF, Culpepper WJ, et al: Multiple sclerosis in gulf war era veterans. 2. Military deployment and risk of multiple sclerosis in the first gulf war. Neuroepidemiology 2014; 42: 226–234.
8.
Walsh SJ, DeChello LM: Excess autoimmune disease mortality among school teachers. J Rheumatol 2001; 28: 1537–1545.
9.
Warren SA, Janzen W, Warren KG, Svenson LW, Schopflocher DP: Multiple Sclerosis Mortality Rates in Canada, 1975–2009. Can J Neurol Sci 2016; 43: 134–141.
10.
Sandi D, Zsiros V, Fuvesi J, et al: Mortality in Hungarian patients with multiple sclerosis between 1993 and 2013. J Neurol Sci 2016; 367: 329–332.
11.
Leray E, Vukusic S, Debouverie M, et al: Excess mortality in patients with multiple sclerosis starts at 20 years from clinical onset: data from a large-scale French observational study. PloS one 2015; 10(7): e0132033.
12.
Redelings MD, McCoy L, Sorvillo F: Multiple sclerosis mortality and patterns of comorbidity in the United States from 1990 to 2001. Neuroepidemiology 2006; 26: 102–107.
13.
Kaufman DW, Reshef S, Golub HL, et al: Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S. Mult Scler Relat Disord 2014; 3: 364–371.
14.
Enstrom JE, Operskalski EA: Multiple sclerosis among Spanish-surnamed Californians. Neurology 1978; 28: 434–438.
15.
Khan O, Williams MJ, Amezcua L, Javed A, Larsen KE, Smrtka JM: Multiple sclerosis in US minority populations: clinical practice insights. Neurol Clin Pract 2015; 5: 132–142.
16.
Harris EC, Palmer KT, Cox V, Darnton A, Osman J, Coggon D: Mortality from multiple sclerosis in British military personnel. Occup Med (Lond) 2017; 67: 448–452.
17.
Capkun G, Dahlke F, Lahoz R, et al. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US department of defense administrative claims database. Mult Scler Relat Disord 2015; 4: 546–554.
18.
Cutter GR, Zimmerman J, Salter AR, et al: Causes of death among persons with multiple sclerosis. Mult Scler Relat Disord 2015; 4: 484–490.
19.
Bove R, Chitnis T: Sexual disparities in the incidence and course of MS. Clin Immunol 2013; 149: 201–210.
20.
Greer JM, McCombe PA: Role of gender in multiple sclerosis: clinical effects and potential molecular mechanisms. J Neuroimmunol 2011; 234: 7–18.
21.
Wallin MT, Culpepper WJ, Coffman P, et al: The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain 2012; 135(pt 6):1778–1785.
22.
Marrie RA, Elliott L, Marriott J, et al: Effect of comorbidity on mortality in multiple sclerosis. Neurology 2015; 85: 240–247.
23.
Weston M, Constantinescu CS: What role does tobacco smoking play in multiple sclerosis disability and mortality? A review of the evidence. Neurodegener Dis Manag 2015; 5: 19–25.
24.
Malkki H: Multiple sclerosis: worrying data on excess mortality and comorbidity in MS. Nat Rev Neurol 2015; 11: 546.
25.
Cree BA, Khan O, Bourdette D, et al: Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology 2004; 63: 2039–2045.
26.
Weinstock-Guttman B, Jacobs LD, Brownscheidle CM, et al: Multiple sclerosis characteristics in African American patients in the New York State Multiple Sclerosis Consortium. Mult Scler 2003; 9: 293–298.
27.
Kister I, Chamot E, Bacon JH, et al: Rapid disease course in African Americans with multiple sclerosis. Neurology 2010; 75: 217–223.
28.
Seraji-Bozorgzad N, Reed S, Bao F, et al. Characterizing retinal structure injury in African-Americans with multiple sclerosis. Mult Scler Relat Disord 2016; 7: 16–20.
29.
Ventura RE, Antezana AO, Bacon T, Kister I: Hispanic Americans and African Americans with multiple sclerosis have more severe disease course than Caucasian Americans. Mult Scler 2017; 23: 1554–1557.
30.
Bichuetti DB, Oliveira EM, Souza NA, Tintore M, Gabbai AA: Patients with neuromyelitis optica have a more severe disease than patients with relapsingremitting multiple sclerosis, including higher risk of dying of a demyelinating disease. Arq Neuropsiquiatr 2013; 71: 275–279.
31.
Flanagan EP, Cabre P, Weinshenker BG, et al: Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol 2016, Epub ahead of print.
32.
Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC: Mortality in patients with multiple sclerosis. Neurology 2013; 81: 184–192.
33.
Shabas D, Heffner M: Multiple sclerosis management for low-income minorities. Mult Scler 2005; 11: 635–640.
34.
Mallinger JB, Lamberti JS: Psychiatrists’ attitudes toward and awareness about racial disparities in mental health care. Psychiatr Serv 2010; 61: 173–179.
35.
Glover Mt, Daye D, Khalilzadeh O, et al: Socioeconomic and demographic predictors of missed opportunities to provide advanced imaging services. J Am Coll Radiol 2017; 14: 1403–1411.
36.
Amezcua L, Conti DV, Liu L, Ledezma K, Langer-Goulda AM: Place of birth, age of immigration,and disability in Hispanics with multiple sclerosis. Mult Scler Relat Disord 2015; 4: 25–30.
37.
Amezcua L, Lund BT, Weiner LP, Islam T: Multiple sclerosis in Hispanics: a study of clinical disease expression. Mult Scler 2011; 17: 1010–1016.
38.
Hadjixenofontos A, Beecham AH, Manrique CP, et al: Clinical expression of multiple sclerosis in hispanic whites of primarily caribbean ancestry. Neuroepidemiology 2015; 44: 262–268.
39.
McCarthy M: CDC report confirms “Hispanic paradox”. BMJ 2015; 350:h2467.
40.
Arias E, Heron M, Hakes J: The validity of race and hispanic-origin reporting on death certificates in the United States: an update. Vital Health Stat 2 2016; 172: 1–21.
41.
Arias E, Eschbach K, Schauman WS, Backlund EL, Sorlie PD: The Hispanic mortality advantage and ethnic misclassification on US death certificates. Am J Public Health 2010; 100(suppl 1):S171–S177.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.